These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1368 related articles for article (PubMed ID: 25916341)

  • 1. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
    Lal H; Cunningham AL; Godeaux O; Chlibek R; Diez-Domingo J; Hwang SJ; Levin MJ; McElhaney JE; Poder A; Puig-Barberà J; Vesikari T; Watanabe D; Weckx L; Zahaf T; Heineman TC;
    N Engl J Med; 2015 May; 372(22):2087-96. PubMed ID: 25916341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
    Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
    N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
    Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
    Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine profile of herpes zoster (HZ/su) subunit vaccine.
    Cunningham AL; Heineman T
    Expert Rev Vaccines; 2017 Jul; 16(7):1-10. PubMed ID: 28486850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
    Schwarz TF; Aggarwal N; Moeckesch B; Schenkenberger I; Claeys C; Douha M; Godeaux O; Grupping K; Heineman TC; Fauqued ML; Oostvogels L; Van den Steen P; Lal H
    J Infect Dis; 2017 Dec; 216(11):1352-1361. PubMed ID: 29029224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
    Chlibek R; Pauksens K; Rombo L; van Rijckevorsel G; Richardus JH; Plassmann G; Schwarz TF; Catteau G; Lal H; Heineman TC
    Vaccine; 2016 Feb; 34(6):863-8. PubMed ID: 26432913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
    Cunningham AL; Heineman TC; Lal H; Godeaux O; Chlibek R; Hwang SJ; McElhaney JE; Vesikari T; Andrews C; Choi WS; Esen M; Ikematsu H; Choma MK; Pauksens K; Ravault S; Salaun B; Schwarz TF; Smetana J; Abeele CV; Van den Steen P; Vastiau I; Weckx LY; Levin MJ;
    J Infect Dis; 2018 May; 217(11):1750-1760. PubMed ID: 29529222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
    Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
    Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
    Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
    Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.
    Kovac M; Lal H; Cunningham AL; Levin MJ; Johnson RW; Campora L; Volpi A; Heineman TC;
    Vaccine; 2018 Mar; 36(12):1537-1541. PubMed ID: 29463421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults.
    Lal H; Zahaf T; Heineman TC
    Hum Vaccin Immunother; 2013 Jul; 9(7):1425-9. PubMed ID: 23584252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial.
    Park JK; Kim M; Jung JI; Kim JY; Jeong H; Park JW; Winthrop KL; Lee EB
    Lancet Rheumatol; 2024 Jun; 6(6):e352-e360. PubMed ID: 38710192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
    Bastidas A; de la Serna J; El Idrissi M; Oostvogels L; Quittet P; López-Jiménez J; Vural F; Pohlreich D; Zuckerman T; Issa NC; Gaidano G; Lee JJ; Abhyankar S; Solano C; Perez de Oteyza J; Satlin MJ; Schwartz S; Campins M; Rocci A; Vallejo Llamas C; Lee DG; Tan SM; Johnston AM; Grigg A; Boeckh MJ; Campora L; Lopez-Fauqued M; Heineman TC; Stadtmauer EA; Sullivan KM;
    JAMA; 2019 Jul; 322(2):123-133. PubMed ID: 31287523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
    Winston DJ; Mullane KM; Cornely OA; Boeckh MJ; Brown JW; Pergam SA; Trociukas I; Žák P; Craig MD; Papanicolaou GA; Velez JD; Panse J; Hurtado K; Fernsler DA; Stek JE; Pang L; Su SC; Zhao Y; Chan ISF; Kaplan SS; Parrino J; Lee I; Popmihajlov Z; Annunziato PW; Arvin A;
    Lancet; 2018 May; 391(10135):2116-2127. PubMed ID: 29856344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults.
    Leroux-Roels I; Leroux-Roels G; Clement F; Vandepapelière P; Vassilev V; Ledent E; Heineman TC
    J Infect Dis; 2012 Oct; 206(8):1280-90. PubMed ID: 22872734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.